Drug intelligence / Profile preview

EG-1961

Development stage: Unknown
Lead developer: PDS Biotech
Administration: Intracranial

Overview

EG-1961 is an investigational, extended-release intracranial formulation of nimodipine being developed to improve outcomes after aneurysmal subarachnoid hemorrhage by providing sustained local cerebrospinal fluid exposure while minimizing systemic toxicity. Designed for placement into the basal cisterns during neurosurgical or endovascular treatment, EG-1961 aims to prevent or reduce cerebral vasospasm and delayed cerebral ischemia through continuous calcium channel blockade of cerebral arteries. The product was developed by Edge Therapeutics (later PDS Biotechnology) as a biodegradable polymer-based nimodipine delivery system to overcome adherence and pharmacokinetic limitations of oral nimodipine therapy in this acute neurocritical care setting.

Brand names: NimoGel

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on EG-1961.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EG-1961.

Explore the full profile